Tocilizumab for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 6, Issue 6, 2010, Pages 843-854

  Tanaka, Toshio ^a   Ogata, Atsushi ^a   Narazaki, Masashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

anti IL 6 receptor monoclonal antibody; IL 6; rheumatoid arthritis; tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STAT3 PROTEIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; VASCULOTROPIN;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLOIDOSIS; ANAPHYLAXIS; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INFECTION; INTESTINE AMYLOIDOSIS; MONOTHERAPY; NEUTROPHIL COUNT; NONHUMAN; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-6; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 78049445876     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.70     Document Type: Review

References (62)

1. Kishimoto T. The biology of interleukin-6. Blood 74(1), 1-10 (1989).
2. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
3. Tanaka T, Katada Y, Suemura M, Kishimoto T. Interleukin-6. In: Cytokine Regulation of Humoral Immunity: Basic and Clinical Aspects. Snapper CM (Ed.). John Wiley & Sons Ltd., Chichester, UK, 251-272 (1996).
4. Kopf M, Baumann H, Freer G et al. Impaired immune and acute-phase responses in interleukin-6-defcient mice. Nature 368, 339-342 (1994).
5. Murakami M, Hibi M, Nakagawa N et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260, 1808-1810 (1993).
6. Narazaki M, Witthuhn BA, Yoshida K et al. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc. Natl Acad. Sci. USA 91(6), 2285-2289 (1994).
7. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 86(4), 1243-1254 (1995).
8. Naka T, Narazaki M, Hirata M et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924-929 (1997).
9. Narazaki M, Yasukawa K, Saito T et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82(4), 1120-1126 (1993).
10. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 76(2), 253-262 (1994).
11. Hirano T, Taga T, Yasukawa K et al. Human B-cell differentiation factor defned by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl Acad. Sci. USA 84(1), 228-231 (1987).
12. Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic signifcance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74(4), 1360-1367 (1989).
13. Hirano T, Matsuda T, Turner M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18, 1797-1801 (1988).
14. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 370, 1861-1874 (2007).
15. Ohshima S, Saeki Y, Mima T et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl Acad. Sci. USA 95(14), 8222-8226 (1998).
16. Choy EH, Isenberg DA, Garrood T et al. Therapeutic beneft of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46, 143-150 (2002).
17. Nishimoto N, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-fnding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 30, 1426-1435 (2003).
18. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004).
19. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817-2829 (2006).
20. Nishimoto N, Miyasaka N, Yamamoto K et al. Long-term safety and effcacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and effcacy in a 5-year extension study. Ann. Rheum. Dis. 68, 1580-1584 (2009).
21. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic beneft from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 1162-1167 (2007).
22. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the TCZ in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968-2980 (2008).
23. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomized placebo controlled trial. Ann. Rheum. Dis. 67(11), 1516-1523 (2008).
24. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 371, 987-997 (2008).
25. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 62, 33-43 (2010).
26. Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): signifcant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19, 12-19 (2009).
27. Fleischmann R. LITHE: Tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients at 2 years with increasing clinical effcacy over time. Presented at: American College of Rheumatology Meeting Pennsylvania, PA, USA, 17-21 October 2009 (Abstract 637).
28. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann. Rheum. Dis. 69, 88-96 (2010).
29. Nishimoto N, Ito K, Takagi N. Safety and effcacy profles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and fve long-term extensions. Mod. Rheumatol. 20(3), 222-232 (2010)
30. Intermediate Report of Post-Marketing Surveillance: Safety Information about ACTEMRA Volume 2. Chugai Pharm. Co., Japan (2009).
31. Koike R, Harigai M, Atsumi T et al. Japanese College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod. Rheumatol. 19, 351-357 (2009).
32. Nam JL, Winthrop KL, van Vollenhoven RF et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 69(6), 976-986 (2010).
33. Gause A, Rubbert-Roth A, Michels H et al. [Recommendations of the German Rheumatology Society on the use of tocilizumab in rheumatoid arthritis]. Z. Rheumatol. 69(4), 365-372 (2010).
34. Fonseca JE, Canhao H, Reis P et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis-March 2010 update. Acta Rheumatol. Port. 35(1), 95-98 (2010).
35. Moots RJ, Ostor AJK, Isaacs JD. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? Expert Opin. Investig. Drugs 18(11), 1687-1699 (2009).
36. Marti L, Scheinberg M. Anti-interleukin 6: a frst line in rheumatoid arthritis? Clin. Rheumatol. 27, 877-879 (2009).
37. Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P. Tocilizumab. Nat Rev. Drug Discov. 8, 273-274 (2009).
38. Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumor necrosis factor inhibitors: what is the next step? Ann. Rheum. Dis. 67, 1497-1498 (2008).
39. Van Ingen J, Boeree MJ, Dekhuizen PN, van Soolingen D. Mycobacterial diseases in patients with rheumatic disease. Nat Clin. Pract Rheumatol. 4(12), 649-656 (2008).
40. Ogata A, Mori M, Hashimoto S et al. Minimal infuence of tocilizumab on IFN-γ synthesis by tuberculosis antigens. Mod. Rheumatol. 20, 130-133 (2010).
41. Ohsugi Y, Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 8(5), 669-681 (2008).
42. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinfammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system Biochem. Biophys. Res. Commun. 314, 363-369 (2004).
43. Hagihara K, Nishikawa T, Sugamata Y et al. Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells 10, 1051-1063 (2005).
44. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 54(9), 2997-3000 (2006).
45. Nishida S, Hagihara K, Shima Y et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann. Rheum. Dis. 68, 1235-1236 (2009).
46. Sato H, Sakai T, Sugaya T et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin. Rheumatol. 28(9), 1113-1116 (2009).
47. Inoue D, Arima H, Kawanami C et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin. Rheumatol. 29(10), 1195-1197 (2010).
48. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T Mechanisms and pathologic signifcances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112(10), 3959-3964 (2008).
49. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohns disease. Gastroenterology 126(4), 989-996 (2004).
50. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 46(12), 3388-3389 (2002).
51. Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Stills disease who was successfully treated with tocilizumab over 6 years. Mod. Rheumatol. 19(1), 69-72 (2009).
52. Matsumoto K, Nagashima T, Takatori S et al. Glucocorticoid and cyclosporine refractory adult onset Stills disease successfully treated with tocilizumab. Clin. Rheumatol. 24(4), 485-487 (2009).
53. Yoshimura M, Makiyama J, Koga T et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin. Exp. Rheumatol. 28(1), 141-142 (2010).
54. De Bandt M, Saint-Marcoux B. Tocilizumab for multirefratory adult-onset Still's disease. Ann. Rheum. Dis. 68(1), 153-154 (2009).
55. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody Arthritis Rheum. 58(4), 1197-1200 (2008).
56. Illei GG, Shirota Y, Yarboro CH et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary effcacy, and impact on circulating plasma cells from an open-label Phase I dosage-escalation study. Arthritis Rheum. 62(2), 542-552 (2010).
57. Kawai M, Hagihara K, Hirano T et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody in two patients with refractory relapsing polychondritis. Rheumatology 48, 318-319 (2009).
58. Tanaka T, Kuwahara Y, Shima Y et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 61, 1762-1764 (2009).
59. Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response to tocilizumab for ankylosing spondylitis. Ann. Rheum. Dis. DOI: 10.1136/ard.2009.126706 (2010) (Epub ahead of print).
60. Tanaka T, Hagihara K, Shima Y et al. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody tocilizumab. Rheumatology 49, 824-826 (2010).
61. Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J. Rheumatol. 37, 1075-1076 (2010).
62. Shima Y, Kuwahara Y, Murota H et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology DOI: 10.1093/rheumatology/keq275 (2010) (Epub ahead of print).